Two-year outcome after biodegradable polymer sirolimus- and biolimus-eluting coronary stents (from the randomised SORT OUT VII trial)
EuroIntervention 2018;13:1587-1590 published online September 2017. DOI: 10.4244/EIJ-D-17-00731
Lisette Okkels Jensen1*, MD, DMSci, PhD; Michael Maeng2, MD, PhD; Bent Raungaard3, MD, PhD; Knud Nørregaard Hansen1, MD; Johnny Kahlert4, MSc; Svend Eggert Jensen3, MD, PhD; Henrik Steen Hansen1, MD, DMSci; Jens Flensted Lassen2, MD, PhD; Hans Erik Bøtker2, MD, DMSci, PhD; Evald Høj Christiansen2, MD, PhD
1. Department of Cardiology, Odense University Hospital, Odense, Denmark; 2. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; 3. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; 4. Department of Clinical Epide
The persistence of polymer material on first- and second-generation coronary drug-eluting stents after completion of drug release has been suggested as a trigger for a chronic